Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Willemieke P M DijksterhuisRob H A VerhoevenSybren L MeijerMarije SlingerlandNadia Haj MohammadJudith de Vos-GeelenLaurens V BeerepootTheo van VoorthuizenGeert-Jan CreemersMartijn G H van OijenHanneke W M van LaarhovenPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)
Increased determination of HER2 and administration of trastuzumab have changed daily practice management of metastatic gastroesophageal cancer patients receiving palliative systemic therapy, and possibly contributed to their improved survival. Further increase in awareness of HER2 testing and trastuzumab administration may improve quality of care and patient outcomes.
Keyphrases
- quality improvement
- healthcare
- squamous cell carcinoma
- small cell lung cancer
- epidermal growth factor receptor
- palliative care
- papillary thyroid
- metastatic breast cancer
- primary care
- physical activity
- squamous cell
- advanced cancer
- stem cells
- pain management
- free survival
- chronic pain
- health insurance
- smoking cessation